Radiation therapy of cutaneous cancers.

{"article_title":"Radiation therapy of cutaneous cancers.","author":"Hennequin C, Rio E, Qu\u00e9ro L, Clav\u00e8re P","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"397","page_count":"","accession_number":"34955421","doi":"10.1016\/j.canrad.2021.11.020","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Skin Neoplasms radiotherapy; Carcinoma, Basal Cell radiotherapy; Carcinoma, Basal Cell surgery; Carcinoma, Merkel Cell radiotherapy; Carcinoma, Squamous Cell radiotherapy; France; Humans; Lymphoma, T-Cell, Cutaneous radiotherapy; Melanoma pathology; Melanoma radiotherapy; Palliative Care; Prognosis; Radiation Oncology; Radiotherapy Dosage; Radiotherapy, Adjuvant; Sarcoma, Kaposi radiotherapy; Skin Neoplasms pathology; Skin Neoplasms surgery","interest_area":["Dermatology"," Oncology"],"abstract":"We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy of cutaneous cancers. The indications of radiotherapy for skin cancers are not clearly defined because of the lack of randomized trials or prospective studies. For basal cell carcinomas, radiotherapy frequently offers a good local control, but a randomized trial showed that surgery is more efficient and less toxic. Indications of radiotherapy are contra-indications of surgery for patients older than 60, non-sclerodermiform histology and located in non-sensitive areas. Adjuvant radiotherapy could be proposed to squamous cell carcinomas, in case of poor prognostic factors. Dose of 60 to 70Gy are usually required, and must be modulated to the size of the lesions. Adjuvant radiotherapy seems beneficial for desmoplastic melanomas but not for the other histological types. Prophylactic nodal irradiation (45 to 50Gy), for locally advanced tumors (massive nodal involvement), decreases the locoregional failure rate but do not increase survival. Adjuvant radio- therapy (50 to 56Gy) for Merkel cell carcinomas increases also the local control rate, as demonstrated by meta-analysis and a large epidemiological study. Nodal areas must be included, if there is no surgical exploration (sentinel lymph node dissection). Kaposi sarcomas are radiosensitive and could be treated with relatively low doses (24 to 30Gy). Also, cutaneous lymphomas are good indications for radiotherapy: B lymphomas are electively treated with limited fields. The role of total skin electron therapy for T-lymphomas is still discussed; but palliative radiotherapy is very efficient in case of cutaneous nodules. Copyright \u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34955421","isPdfLink":false,"isSAML":true,"an":"34955421","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211227 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 397-403. Date of Electronic Publication: 2021 Dec 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy of cutaneous cancers. The indications of radiotherapy for skin cancers are not clearly defined because of the lack of randomized trials or prospective studies. For basal cell carcinomas, radiotherapy frequently offers a good local control, but a randomized trial showed that surgery is more efficient and less toxic. Indications of radiotherapy are contra-indications of surgery for patients older than 60, non-sclerodermiform histology and located in non-sensitive areas. Adjuvant radiotherapy could be proposed to squamous cell carcinomas, in case of poor prognostic factors. Dose of 60 to 70Gy are usually required, and must be modulated to the size of the lesions. Adjuvant radiotherapy seems beneficial for desmoplastic melanomas but not for the other histological types. Prophylactic nodal irradiation (45 to 50Gy), for locally advanced tumors (massive nodal involvement), decreases the locoregional failure rate but do not increase survival. Adjuvant radio- therapy (50 to 56Gy) for Merkel cell carcinomas increases also the local control rate, as demonstrated by meta-analysis and a large epidemiological study. Nodal areas must be included, if there is no surgical exploration (sentinel lymph node dissection). Kaposi sarcomas are radiosensitive and could be treated with relatively low doses (24 to 30Gy). Also, cutaneous lymphomas are good indications for radiotherapy: B lymphomas are electively treated with limited fields. The role of total skin electron therapy for T-lymphomas is still discussed; but palliative radiotherapy is very efficient in case of cutaneous nodules.<br \/> (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/dx.doi.org\/doi:10.1016\/j.canrad.2021.11.020","no_of_pages":"","authored_by":"Hennequin C, Rio E, Qu\u00e9ro L, Clav\u00e8re P","additionalInfo":{"Authored_By":"Hennequin C, Rio E, Qu\u00e9ro L, Clav\u00e8re P","Journal_Info":"Publisher: Elsevier Country of Publication: France NLM ID: 9711272 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1769-6658 (Electronic) Linking ISSN: 12783218 NLM ISO Abbreviation: Cancer Radiother Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline","Published_Date":"2022-02-01","Source":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 397-403. Date of Electronic Publication: 2021 Dec 23.","Languages":"English","Electronic_ISSN":"1769-6658","MeSH_Terms":"Skin Neoplasms\/*radiotherapy, Carcinoma, Basal Cell\/radiotherapy ; Carcinoma, Basal Cell\/surgery ; Carcinoma, Merkel Cell\/radiotherapy ; Carcinoma, Squamous Cell\/radiotherapy ; France ; Humans ; Lymphoma, T-Cell, Cutaneous\/radiotherapy ; Melanoma\/pathology ; Melanoma\/radiotherapy ; Palliative Care ; Prognosis ; Radiation Oncology ; Radiotherapy Dosage ; Radiotherapy, Adjuvant ; Sarcoma, Kaposi\/radiotherapy ; Skin Neoplasms\/pathology ; Skin Neoplasms\/surgery","Subjects":"Carcinoma, Basal Cell radiotherapy, Carcinoma, Basal Cell surgery, Carcinoma, Merkel Cell radiotherapy, Carcinoma, Squamous Cell radiotherapy, France, Humans, Lymphoma, T-Cell, Cutaneous radiotherapy, Melanoma pathology, Melanoma radiotherapy, Palliative Care, Prognosis, Radiation Oncology, Radiotherapy Dosage, Radiotherapy, Adjuvant, Sarcoma, Kaposi radiotherapy, Skin Neoplasms pathology, Skin Neoplasms surgery, Skin Neoplasms radiotherapy","Title_Abbreviations":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","Volume":"26"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"34955421","RelevancyScore":"811","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"810.871276855469"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34955421&authtype=shib&custid=ns346513&group=main&profile=eds"}